Atrial fibrillation is a common heart rhythm disorder in which the upper chambers of the heart beat irregularly and often rapidly. It can reduce the heart's pumping efficiency and raise the risk of stroke and other complications.
A retrospective cohort study of 14,118 matched pairs found tirzepatide associated with lower risks of stroke and death than other GLP-1 receptor agonists in patients with atrial fibrillation and type 2 diabetes. Absolute differences were 2.1 percentage points for stroke and 6.2 for mortality at one year. Randomized trials are needed before recommendations change.
First-line pulsed field ablation achieved 56% vs 30% success with drugs in persistent AFib (HR 0.46). Device-related serious adverse events occurred in 5.1%. Results published in NEJM.
The International Cardio-Oncology Society has released new guidelines for managing cancer therapy-related cardiac dysfunction, addressing educational gaps identified in a survey of 220 healthcare providers. The survey found highest educational needs for topics like immune checkpoint inhibitor-associated myocarditis and atrial fibrillation management.
The U.S. cardiovascular drugs market is projected to reach $37.03 billion by 2035, growing at a CAGR of 2.68%. Europe's anticoagulants market is expected to reach $23.68 billion by 2033, expanding at a CAGR of 8.22%.
Experts discuss balancing efficacy and safety in BTK inhibitor plus venetoclax combination therapy for CLL, including BTK lead-in strategies to reduce tumor lysis syndrome risk and the benefits of all-oral fixed-duration regimens.
Medtronic reported interim Affera Sphere-9 data showing 65.5% of VT patients were free from recurrence at six months. The FDA granted Breakthrough Device designation for Sphere-9 and approved a U.S. pivotal IDE.
A study found seniors with screening-detected atrial fibrillation had a roughly threefold higher risk of heart failure. Heart failure was often diagnosed within six months.
Wearable technologies are transforming clinical trials and healthcare with continuous monitoring capabilities, though clinical validation remains limited. While ECG features provide useful data for cardiac monitoring, many wearable metrics lack clinical accuracy and can cause patient anxiety. The technology shows promise for activity tracking and specific medical applications but requires cautious interpretation.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
New research shows patients on GLP-1 drugs may need to delay endoscopy procedures due to retained gastric contents, while a Cleveland Clinic study found 45% of obesity patients maintained weight loss one year after stopping the medications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779746 |
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07776054 |
Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF |
RECRUITING | PHASE4 |
| NCT07752758 |
Ezetimibe for Arrhythmia Recurrence After AF Ablation |
NOT_YET_RECRUITING | PHASE4 |
| NCT07741682 |
The Effect of an Intervention Based on The CSM on Self-Management in Patients After Atrial Fibrillation Ablation |
COMPLETED | NA |
| NCT07724301 |
Regulation of Platelet Function in Older Patients With Atrial Fibrillation |
NOT_YET_RECRUITING | |
| NCT07724171 |
Long-term Outcomes After Percutaneous Patent Foramen Ovale Closure (Severance PFO Registry) |
RECRUITING | |
| NCT07715929 |
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients |
NOT_YET_RECRUITING | PHASE4 |
| NCT07697469 |
Atrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization |
NOT_YET_RECRUITING | |
| NCT07651852 |
Globe Registry: Globe® Pulsed Field System Registry Study for Treating Patients With Symptomatic Atrial Fibrillation |
NOT_YET_RECRUITING | |
| NCT07638995 |
Single Chamber Atrial Leadless Pacing for Isolated Sinus Node Dysfunction |
RECRUITING |
